RapidAI has expanded its deep clinical AI capabilities with five new FDA clearances for its Rapid Enterprise Platform, enhancing precision in radiology and advancing neurology and vascular care. The newly cleared modules—Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement—represent a major leap forward in intelligent imaging solutions designed to support clinicians throughout the entire patient journey. Rapid DeltaFuse enables automatic alignment and co-registration of serial non-contrast head CT scans, allowing clinicians to detect subtle intracranial changes such as hemorrhages, masses, or ventricular shifts over time. Studies show it reduces radiologist comparison time by more than 36%, improving long-term patient management. Rapid LMVO extends full brain coverage on CTA, including anterior, posterior, basilar, and distal territories, solidifying RapidAI’s leadership in ischemic stroke care. When combined with perfusion and non-contrast imaging tools, the platform offers a complete stroke solution from initial detection to advanced analysis—backed by the only CT and MR perfusion analysis clinically validated in randomized trials. Rapid MLS provides accurate detection and quantification of midline shift, a critical sign of brain injury, with a mean absolute error of just 0.8 mm, enabling earlier and more reliable clinical decisions. Rapid OH identifies suspected obstructive hydrocephalus by detecting cerebrospinal fluid accumulation in the lateral ventricles and generates alerts in under a minute, accelerating triage and transfer decisions. It is also eligible for the CMS New Technology Add-on Payment, highlighting its clinical and economic value. Rapid Aortic analyzes any CT scan involving the aorta—whether non-contrast or post-treatment—delivering guideline-based measurements with consistent, reader-independent results. It includes advanced 3D reconstruction, automated longitudinal comparisons, and follow-up notifications, streamlining surveillance and supporting confident surgical planning. Karim Karti, CEO of RapidAI, emphasized the company’s focus on deep clinical AI that goes beyond triage. “Our algorithms are designed to reduce cognitive burden, support acute care decisions, and improve long-term patient management—enabling radiologists to practice at the top of their license,” he said. Clinicians are already seeing the impact. Dr. Kiran Nandalur, Medical Director at Corewell Health Radiology, noted that RapidAI’s automation reduces the need for manual data handling, allowing radiologists to focus on clinical judgment and patient care. All modules are integrated into the Rapid Edge Cloud, a cloud-first platform with on-prem options ensuring continuous operation during disruptions. They also work seamlessly within Rapid Navigator Pro, the company’s next-generation radiology solution, as well as mobile and web applications, enabling secure, unified access across PACS, EHR, and reporting systems. With over 2,500 hospitals in more than 100 countries using the platform and supported by 700+ clinical studies—including research that helped shape national stroke treatment guidelines—RapidAI remains the most clinically validated AI platform in healthcare. The new clearances further establish its role in delivering intelligent, integrated, and scalable imaging solutions that improve outcomes and system performance.